Loading clinical trials...

Antibodies and Immunity After Vaccination of Recovered Patients With COVID-19 and Long COVID-19 Symptoms | Clinical Trials | Clareo Health

UNKNOWN

Antibodies and Immunity After Vaccination of Recovered Patients With COVID-19 and Long COVID-19 Symptoms

SARS-CoV-2 Neutralizing Antibodies and Immunity After Vaccination of Recovered Patients With COVID-19 and Correlation With Immunity and Long-COVID-19 Symptoms

NCT05484700•Mahidol University

View on ClinicalTrials.gov

Summary

We investigated the association between immune system responsibilities in Long COVID patients and Full recovery patients.

Detailed Description

This retrospective cohort study compared immunogenicity post COVID-19 between individuals (aged 18-65 years and had confirmed SARS-CoV-2 infection from January to May 2022 ) with residual Long COVID-19 symptoms (LC) and ones with full recovery (Full) related to pathophysiology, immunology and clinical consequence.

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Long COVID group; at longer than 1-month post COVID-19 based the presence of one of the three following symptoms: fatigue/myalgia, breathlessness, and anorexia
•Full recovery group; patients with asymptomatic symptoms
•post COVID-19 they had not received any additional COVID vaccine

Exclusion Criteria

•people who received additional vaccination after leaving quarantine before the day of the immunization test
•pregnant patients,
•people who had a history of allergic reactions after COVID-19 vaccination or any drugs

Locations (1)

Faculty of Medicine Siriraj Hospital, Mahidol University

Bangkok Noi, Bangkok, Thailand

Key Dates

Start Date

December 30, 2021

Primary Completion Date

July 25, 2022

Completion Date

December 29, 2022

Last Updated

August 5, 2022

Enrollment

305

ESTIMATED participants

Conditions

Long COVID-19

LOng COvid COmorbidities: Andrological, Reproductive, Sexual Dysfunctions in Patients Recovered From COVID-19

NCT05379556

Long Covid-19

View study

RECRUITINGPHASE3

Low Dose Sirolimus in People With Post-Acute Sequelae of COVID-19 (PASC) Long COVID-19

NCT06960928

Long COVID-19

View study

ACTIVE_NOT_RECRUITINGPHASE2

RECOVER-AUTONOMIC: Platform Protocol, Appendix A (IVIG)

NCT06305793

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 5, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Antibodies and Immunity After Vaccination of Recovered Patients With COVID-19 and Long COVID-19 Symptoms

Inclusion Criteria

Exclusion Criteria

LOng COvid COmorbidities: Andrological, Reproductive, Sexual Dysfunctions in Patients Recovered From COVID-19

Low Dose Sirolimus in People With Post-Acute Sequelae of COVID-19 (PASC) Long COVID-19

RECOVER-AUTONOMIC: Platform Protocol, Appendix A (IVIG)

Synbiotic Therapy for NP-PASC

Evaluating the Impact of a Functional and Cognitive Strategy in Patients with Long Covid-19

Long Term Impact of COVID-19